

Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/AC8CBB60B525EN.html>

Date: March 2022

Pages: 197

Price: US\$ 2,000.00 (Single User License)

ID: AC8CBB60B525EN

Abstracts

Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 13, 8, 3, 42, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development

A6 Pharmaceuticals LLC

Abbreos Inc

AcelRx Pharmaceuticals Inc

Aktyva Therapeutics Inc

Alveolus Bio Inc

AMNICELL Corp Ltd

Ampio Pharmaceuticals Inc

APEIRON Biologics AG

ARBORMED Pharmaceuticals Inc

Arch Biopartners Inc

Athersys Inc

Avalon GloboCare Corp

Aviceda Therapeutics

AVM Biotechnology LLC

Bayer AG

Biocon Ltd

BioMarck Pharmaceuticals Ltd

BioStem Technologies Inc

Bioxytran Inc

Bonus BioGroup Ltd

Cartesian Therapeutics Inc

Cellular Biomedicine Group Ltd
Cellvation Inc
Celularity Inc
Curacle Co Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dianomi Therapeutics Inc
Emergent BioSolutions Inc
Endece LLC
Enlivex Therapeutics Ltd
Eunoia Biotech LLC
Exvastat Ltd
Faron Pharmaceuticals Oy
GentiBio Inc
Green Cross LabCell Corp
Grifols SA
Haisco Pharmaceutical Group Co Ltd
HistoCell SL
ImmunityBio Inc
Implicit Bioscience Ltd
Imstem Biotechnology Inc
In2cure AB
IsletOne AB
Kalvista Pharmaceuticals Inc
Kubota Vision Inc
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
MannKind Corp
MDI Therapeutics Inc
MediPost Co Ltd
Medsenic SAS
Meridigen Biotech Co Ltd
Nano Biotherapeutics Inc
Neutrolis Inc
Northern Therapeutics Inc
NS Pharma Inc
Nuvara Therapeutics LLC
OGB1 Inc

Omnispirant Ltd
Orion Biotechnology Canada Ltd
Pantherna Therapeutics GmbH
PharmAbcine Inc
Restore Therapeutics LLC
RION Health Inc
Shanghai Henlius Biotech Inc
SolAeroMed Inc
Sorrento Therapeutics Inc
Systimmune Inc
Thetis Pharmaceuticals LLC
Vasomune Inc
Veru Inc
Windtree Therapeutics Inc
Xfibra Inc
Xintela AB
ZyVersa Therapeutics Inc
Acute Respiratory Distress Syndrome - Drug Profiles
(cannabidiol + hydroxychloroquine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
A6-5188 - Drug Profile
Product Description
Mechanism Of Action
AB-5000 - Drug Profile
Product Description
Mechanism Of Action
ABB-201 - Drug Profile
Product Description
Mechanism Of Action
abivertinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
AKT-001 - Drug Profile
Product Description
Mechanism Of Action
alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description
Mechanism Of Action
History of Events
Ampion - Drug Profile
Product Description
Mechanism Of Action
History of Events
APN-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ApoCell - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARBM-201 - Drug Profile
Product Description
Mechanism Of Action
AV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVD-1010 - Drug Profile
Product Description
Mechanism Of Action
BAY-1097761 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BAY-1211163 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BDTp-231 - Drug Profile
Product Description
Mechanism Of Action
BIO-11006 - Drug Profile
Product Description
Mechanism Of Action

History of Events

Biologic for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory - Drug Profile

Product Description

Mechanism Of Action

Biologics for Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

BSEM-001 - Drug Profile

Product Description

Mechanism Of Action

BSEM-002 - Drug Profile

Product Description

Mechanism Of Action

BSEM-003 - Drug Profile

Product Description

Mechanism Of Action

BXT-25 - Drug Profile

Product Description

Mechanism Of Action

CBMSC-1 - Drug Profile

Product Description

Mechanism Of Action

CEVA-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CT-303 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CU-06 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CYNK-001 - Drug Profile

Product Description
Mechanism Of Action
History of Events
Descartes-30 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
DTX-020 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DWP-710 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
HCR-040 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HLX-70 - Drug Profile
Product Description
Mechanism Of Action
HSK-31858 - Drug Profile
Product Description
Mechanism Of Action
ibudilast - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-14 - Drug Profile

Product Description
Mechanism Of Action
History of Events
IC-200 - Drug Profile
Product Description
Mechanism Of Action
ilginatinib - Drug Profile
Product Description
Mechanism Of Action
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
IMS-001 - Drug Profile
Product Description
Mechanism Of Action
interferon beta-1a - Drug Profile
Product Description
Mechanism Of Action
History of Events
invimestrocel - Drug Profile
Product Description
Mechanism Of Action
History of Events
IO-2 - Drug Profile
Product Description
Mechanism Of Action
itolizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
KV-998052 - Drug Profile
Product Description
Mechanism Of Action
LT-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LTX-608 - Drug Profile

Product Description
Mechanism Of Action
History of Events
MCS-222 - Drug Profile
Product Description
Mechanism Of Action
MDI-2517 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MesenCure - Drug Profile
Product Description
Mechanism Of Action
History of Events
Metablok - Drug Profile
Product Description
Mechanism Of Action
History of Events
NAV-5093 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
NTR-452 - Drug Profile
Product Description
Mechanism Of Action
OB-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OS-002 - Drug Profile
Product Description
Mechanism Of Action
PAN-004 - Drug Profile
Product Description
Mechanism Of Action
PAN-006 - Drug Profile

Product Description
Mechanism Of Action
PAN-007 - Drug Profile
Product Description
Mechanism Of Action
Peptide for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
piceatannol albumin bound - Drug Profile
Product Description
Mechanism Of Action
History of Events
plasminogen (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PMC-402 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Polymer for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
PXVX-0047 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REGEND-007 - Drug Profile
Product Description
Mechanism Of Action
REGEND-008 - Drug Profile
Product Description
Mechanism Of Action
S-1229 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sabizabulin - Drug Profile

Product Description
Mechanism Of Action
History of Events
SIF-019 - Drug Profile
Product Description
Mechanism Of Action
History of Events
simvastatin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory
Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit VAP-1 for Ophthalmology and Acute Respiratory Distress
Syndrome - Drug Profile
Product Description
Mechanism Of Action
SMUPIV-01 - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19) - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Infectious Diseases and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides for Acute Lung Injury and Acute Respiratory Distress Syndrome -
Drug Profile
Product Description
Mechanism Of Action
TCP-25 - Drug Profile
Product Description
Mechanism Of Action
TP-317 - Drug Profile
Product Description
Mechanism Of Action

History of Events

UMC-11906 - Drug Profile

Product Description

Mechanism Of Action

UMC-11912 - Drug Profile

Product Description

Mechanism Of Action

Viral Acute Respiratory Distress Syndrome (V-ARDS) - Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-025 - Drug Profile

Product Description

Mechanism Of Action

XFB-19 - Drug Profile

Product Description

Mechanism Of Action

History of Events

XSTEM - Drug Profile

Product Description

Mechanism Of Action

History of Events

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: Healios plans preapplication consultation with PMDA on MultiStem as early as March

Feb 03, 2022: Faron Pharmaceuticals : Scientific reports publishes INFORAAA results showing traumakine-induced up-regulation of CD73 prevents death after emergency open aortic surgery

Jan 26, 2022: Athersys to host a virtual presentation on its MultiStem programs

Nov 30, 2021: Report of placebo-controlled clinical trial evaluating Multistem cell therapy for acute respiratory distress syndrome published in intensive care medicine

Nov 12, 2021: Athersys reports updates on timing for Japan ARDS and stroke programs from Healios K.K.

Sep 28, 2021: Athersys to present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference

Aug 09, 2021: Healios reports positive data of cell therapy in ARDS patients

Jul 21, 2021: Enlivex to present at the Improvate Life-Saving Technologies International Conference 2021

Jul 14, 2021: Enlivex to present at the ARDS Drug Development Summit 2021

Jul 07, 2021: Results of Biomarck clinical and preclinical studies of BIO-11006 in ARDS to be presented at the 2021 ARDS Drug Development Summit

Jun 30, 2021: New publication provides further clarity of multistem's mechanism of action on modulating the inflammatory response in critical care indications

Jun 28, 2021: MediciNova to conduct mouse study under partnership with BARDA to develop MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury

May 12, 2021: Results of Biomarck phase II study of BIO-11006 in patients with ARDS to be presented at the 2021 ATS Annual Meeting

Apr 06, 2021: Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK

Mar 31, 2021: Athersys reports that healios has completed enrollment in the ONE-BRIDGE study of MultiStem for Acute Respiratory Distress Syndrome in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, 2022

Acute Respiratory Distress Syndrome - Pipeline by Abbreos Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by AcelRx Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Aktyva Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Alveolus Bio Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by AMNICELL Corp Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Ampio Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by APEIRON Biologics AG, 2022

Acute Respiratory Distress Syndrome - Pipeline by ARBORMED Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Arch Biopartners Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Avalon GloboCare Corp, 2022

Acute Respiratory Distress Syndrome - Pipeline by Aviceda Therapeutics, 2022

Acute Respiratory Distress Syndrome - Pipeline by AVM Biotechnology LLC, 2022

Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, 2022

Acute Respiratory Distress Syndrome - Pipeline by Biocon Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by BioStem Technologies Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Bioxytran Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Bonus BioGroup Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Cartesian Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Cellular Biomedicine Group Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Cellvation Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Celularity Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Curacle Co Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Cytonus Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Dianomi Therapeutics Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Emergent BioSolutions Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Endece LLC, 2022

Acute Respiratory Distress Syndrome - Pipeline by Enlivex Therapeutics Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Eunoia Biotech LLC, 2022

Acute Respiratory Distress Syndrome - Pipeline by Exvastat Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, 2022

Acute Respiratory Distress Syndrome - Pipeline by GentiBio Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Green Cross LabCell Corp, 2022

Acute Respiratory Distress Syndrome - Pipeline by Grifols SA, 2022

Acute Respiratory Distress Syndrome - Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by HistoCell SL, 2022

Acute Respiratory Distress Syndrome - Pipeline by ImmunityBio Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Imstem Biotechnology Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by In2cure AB, 2022

Acute Respiratory Distress Syndrome - Pipeline by IsletOne AB, 2022

Acute Respiratory Distress Syndrome - Pipeline by Kalvista Pharmaceuticals Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Kubota Vision Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by Liminal BioSciences Inc, 2022

Acute Respiratory Distress Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, 2022

Acute Respiratory Distress Syndrome - Pipeline by MannKind Corp, 2022

Acute Respiratory Distress Syndrome - Pipeline by MDI Therapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by MediPost Co Ltd, 2022
Acute Respiratory Distress Syndrome - Pipeline by Medsenic SAS, 2022
Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, 2022
Acute Respiratory Distress Syndrome - Pipeline by Nano Biotherapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Neutrolis Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Northern Therapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by NS Pharma Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Nuvara Therapeutics LLC, 2022
Acute Respiratory Distress Syndrome - Pipeline by OGB1 Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Omnispirant Ltd, 2022
Acute Respiratory Distress Syndrome - Pipeline by Orion Biotechnology Canada Ltd, 2022
Acute Respiratory Distress Syndrome - Pipeline by Pantherna Therapeutics GmbH, 2022
Acute Respiratory Distress Syndrome - Pipeline by PharmAbcine Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Restore Therapeutics LLC, 2022
Acute Respiratory Distress Syndrome - Pipeline by RION Health Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Shanghai Henlius Biotech Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Sorrento Therapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Systimmune Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Thetis Pharmaceuticals LLC, 2022
Acute Respiratory Distress Syndrome - Pipeline by Vasomune Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Veru Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Xfibra Inc, 2022
Acute Respiratory Distress Syndrome - Pipeline by Xintela AB, 2022
Acute Respiratory Distress Syndrome - Pipeline by ZyVersa Therapeutics Inc, 2022
Acute Respiratory Distress Syndrome - Dormant Projects, 2022
Acute Respiratory Distress Syndrome - Dormant Projects, 2022 (Contd..1)
Acute Respiratory Distress Syndrome - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AC8CBB60B525EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC8CBB60B525EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

